Glycopyrronium Bromide: Uses, Pharmacology, and Clinical Applications
Glycopyrronium bromide, also known as glycopyrrolate in the United States, is a synthetic quaternary ammonium compound used in various medical settings. As a member of the muscarinic anticholinergic group, it works by blocking muscarinic receptors, which are a type of receptor in the nervous system that regulates various bodily secretions and muscle contractions.
One of the defining characteristics of glycopyrronium bromide is that it does not cross the blood-brain barrier. Because it cannot enter the central nervous system, it produces few to no central effects, making it a peripherally-selective antimuscarinic agent.
[ไม่มีภาพประกอบ]
Key Facts
- Drug Class: Peripherally-selective antimuscarinic.
- Primary Use: Treatment of excessive sweating (hyperhidrosis) and other anticholinergic applications.
- Administration: Available via inhalation, oral, intravenous, subcutaneous, topical, and injection routes.
- Key Feature: Does not cross the blood-brain barrier, limiting central nervous system side effects.
- Global Status: Included on the World Health Organization's List of Essential Medicines.
Clinical Applications and Regulatory History
Glycopyrronium bromide is marketed under several trade names, including Robinul, Cuvposa, and Seebri. Its clinical utility spans multiple delivery methods to suit different medical needs.
In September 2012, the medication was approved for medical use within the European Union. A significant milestone occurred in June 2018, when the U.S. Food and Drug Administration (FDA) approved it specifically for the treatment of excessive underarm sweating. This marked the first time a drug was developed specifically for the reduction of excessive sweating.
Pharmacology and Chemical Properties
Chemically, the active moiety of the drug is the cation, referred to as glycopyrronium (INN) or glycopyrrolate (USAN). Its molecular formula is C19H28BrNO3 with a molar mass of 398.341 g·mol.
Pharmacokinetics
The drug is processed and eliminated relatively quickly by the body. It has an elimination half-life ranging from 0.6 to 1.2 hours. Excretion occurs primarily through the kidneys (85%), with an unknown amount excreted via the bile.
| Property | Detail |
|---|---|
| IUPAC Name | 3-[2-Cyclopentyl(hydroxy)phenylacetoxy]-1,1-dimethylpyrrolidinium bromide |
| CAS Number | 51186-83-5 |
| ATC Codes | A03AB02, D11AA01, R03BB06 |
| Pregnancy Category | AU: B2 |
| Legal Status | Prescription only (Rx) in US, UK, EU, CA, and AU |
Side Effects and Precautions
While glycopyrronium bromide avoids central nervous system effects, it can cause several peripheral side effects due to its antimuscarinic action. These commonly include:
- Dry mouth and reduced secretions in the airways.
- Gastrointestinal issues: Constipation, diarrhea, nausea, and vomiting.
- Urinary retention.
- Other reactions: Flushing, nasal congestion, and irritability.
Frequently Asked Questions
What is glycopyrronium bromide used for?
It is used as an antimuscarinic agent and was specifically approved by the FDA in 2018 to treat excessive underarm sweating.
Does this medication affect the brain?
No, glycopyrronium bromide does not cross the blood-brain barrier, which means it has few to no effects on the central nervous system.
How is the drug administered?
It can be administered through several routes, including inhalation, by mouth, intravenously, subcutaneously, via injection, or topically.
What are the most common side effects?
Common side effects include dry mouth, constipation, nausea, vomiting, urinary retention, and reduced airway secretions.
How is glycopyrronium bromide eliminated from the body?
The drug is primarily excreted by the kidneys (85%), with a relatively short elimination half-life of 0.6 to 1.2 hours.